Fatal Septic Shock with Presumed Urinary Source in a Patient with Clinically Suspected, Previously Undiagnosed Von Hippel–Lindau Disease: A Case Report and Literature Review
Downloads
DOI:
https://doi.org/10.71079/ASIDE.IM.062426791Abstract
Background: Von Hippel-Lindau disease is a rare form of autosomal dominant cancer syndrome that affects multiple organs, such as the retina and brain hemangioblastoma, renal disease, and other visceral malignancies. Delayed diagnosis is a significant reason for avoidable mortality and morbidity.
Case Presentation: We present a case of a 47-year-old male presenting with fever, vomiting, hypotension, and pus discharge from his urethral catheter, developing into septic shock with multiple organ dysfunction syndrome. He had several decades of progressive symptoms clinically compatible with possible VHL syndrome, consisting of bilateral blindness secondary to globe enucleations performed since childhood, multifocal spinal cord lesions resulting in quadriparesis and neurogenic bladder, and a family history of retinoblastoma, brain tumors, and renal lesions. MRI of the spine showed extensive multifocal intramedullary enhancing lesions, from the cervicomedullary junction to T11, associated with dilated cord due to cystic changes, compression of the posterior medulla leading to obstructive hydrocephalus, and an occipital lesion. These findings favored multiple spinal hemangioblastomas. A corticomedullary cyst of the right kidney was seen. Despite intensive supportive therapy and appropriate broad-spectrum antibiotics, he succumbed to septic shock complicated by a presumed urinary source on hospital day 4.
Conclusion: This particular case illustrates the potential of unidentified genetic tumors resulting in significant neurological problems and infections leading to death. Early detection of multifocal hemangioblastomas and retinal problems can lead to early identification of patients at risk of developing VHL disease.
Keywords:
Von Hippel–Lindau disease, Hemangioblastoma, Urosepsis, Septic shock, Spinal cord tumor, Retinal hemangioblastoma, Phthisis bulbi, Delayed diagnosis, Hereditary tumor syndromeReferences
1. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau disease. Lancet. 2003: 2059 [PMID: 12814730 10.1016/S0140-6736(03)13643-4] DOI: https://doi.org/10.1016/S0140-6736(03)13643-4
2. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011: 617 [PMID: 21386872 10.1038/ejhg.2010.175] DOI: https://doi.org/10.1038/ejhg.2010.175
3. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993: 1317 [PMID: 8493574 10.1126/science.8493574] DOI: https://doi.org/10.1126/science.8493574
4. Kaelin WG, Jr. The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. Trans Am Clin Climatol Assoc. 2017: 298 [PMID: 28790514
5. Van Leeuwaarde RS, Ahmad S, van Nesselrooij B, Giles RH. Von Hippel-Lindau Syndrome. GeneReviews [Internet]. Seattle (WA): University of Washington; 2024.
6. Melmon KL, Rosen SW. Lindau's Disease. Review of the Literature and Study of a Large Kindred. Am J Med. 1964: 595 [PMID: 14142412 10.1016/0002-9343(64)90107-x] DOI: https://doi.org/10.1016/0002-9343(64)90107-X
7. Louise MBM, Smerdel M, Borgwadt L, Beck Nielsen SS, Madsen MG, Moller HU, Kiilgaard JF, Friis-Hansen L, Harbud V, Cortnum S, Owen H, Gimsing S, Friis Juhl HA, Munthe S, Geilswijk M, Rasmussen AK, Moldrup U, Graumann O, Donskov F, Gronbaek H, Stausbol-Gron B, Schaffalitzky de Muckadell O, Knigge U, Dam G, Wadt KA, Bogeskov L, Bagi P, Lund L, Stochholm K, Ousager LB, Sunde L. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. Eur J Med Genet. 2022: 104538 [PMID: 35709961 10.1016/j.ejmg.2022.104538] DOI: https://doi.org/10.1016/j.ejmg.2022.104538
8. Crossey PA, Eng C, Ginalska-Malinowska M, Lennard TW, Wheeler DC, Ponder BA, Maher ER. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet. 1995: 885 [PMID: 8592333 10.1136/jmg.32.11.885] DOI: https://doi.org/10.1136/jmg.32.11.885
9. Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A Review of Von Hippel-Lindau Syndrome. J Kidney Cancer VHL. 2017: 20 [PMID: 28785532 10.15586/jkcvhl.2017.88] DOI: https://doi.org/10.15586/jkcvhl.2017.88
10. Acharya A, Panigrahi S, Mahapatra AK, Deo RC, Senapati SB. Von-Hippel Lindau (VHL) syndrome with bilateral cerebellar hemangioblastomas and retinal angiomas: A rare presentation. Int J Surg Case Rep. 2023: 108188 [PMID: 37080144 10.1016/j.ijscr.2023.108188] DOI: https://doi.org/10.1016/j.ijscr.2023.108188
11. Setyawan NH, Hartanto RA, Malueka RG, Dwianingsih EK, Dharma DP. Dual manifestations: spinal and cerebellar hemangioblastomas indicative of von Hippel-Lindau syndrome. Radiol Case Rep. 2024: 5000 [PMID: 39247472 10.1016/j.radcr.2024.07.158] DOI: https://doi.org/10.1016/j.radcr.2024.07.158
12. Kreatsoulas DC, Lonser RR. Spinal cord hemangioblastomas in von Hippel-Lindau disease. Neurooncol Adv. 2024: iii66 [PMID: 39430395 10.1093/noajnl/vdad153] DOI: https://doi.org/10.1093/noajnl/vdad153
13. Kim OH. Multifocal Spinal Hemangioblastoma in von Hippel-Lindau Syndrome: A Case Report and Literature Review. Journal of the Korean Society of Radiology. 2015: 10.3348/jksr.2015.72.3.171] DOI: https://doi.org/10.3348/jksr.2015.72.3.171
14. Nguyen TH, Pham T, Strickland T, Brewer D, Belirgen M, Al-Rahawan MM. Von Hippel-Lindau with early onset of hemangioblastoma and multiple drop-metastases like spinal lesions: A case report. Medicine (Baltimore). 2018: e12477 [PMID: 30278534 10.1097/MD.0000000000012477] DOI: https://doi.org/10.1097/MD.0000000000012477
15. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, Investigators MK. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021: 2036 [PMID: 34818478 10.1056/NEJMoa2103425] DOI: https://doi.org/10.1056/NEJMoa2103425
16. Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, Bloomquist EW, Charlab R, Hamed SS, Miller CP, Dorff SE, Chambers WA, Mixter BD, Dinin J, Pierce WF, Ricks TK, Tang S, Donoghue M, Pazdur R, Amiri-Kordestani L, Ibrahim A, Beaver JA. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors. Clin Cancer Res. 2022: 4843 [PMID: 35727604 10.1158/1078-0432.CCR-22-1054] DOI: https://doi.org/10.1158/1078-0432.CCR-22-1054
17. Karimi S, Arabi A, Shahraki T, Safi S. Von Hippel-Lindau Disease and the Eye. J Ophthalmic Vis Res. 2020: 78 [PMID: 32095212 10.18502/jovr.v15i1.5950] DOI: https://doi.org/10.18502/jovr.v15i1.5950
18. Chew EY. Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans Am Ophthalmol Soc. 2005: 495 [PMID: 17057815
License
Copyright (c) 2026 Talha Khan, Hasnain Wajeeh Saqib, Syed Tahir Hussain , Ahmad Mustafa Butt, Muhammad Hassaan Javaid, Awais Hussain Kazim, Aqsa Ibrahim , Saif Ali Khan , Noor Ül-Izza, Abdullah Abbas

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright and Licensing
All articles published in ASIDE Internal Medicine are open access and freely available online immediately upon publication, without embargo.
This journal applies the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license, anyone may copy, redistribute, remix, transform, and build upon the material for any purpose, even commercially, provided that proper credit is given to the original author(s), a link to the license is provided, and any changes made are indicated.
-
License link: https://creativecommons.org/licenses/by/4.0/
-
Machine-readable license metadata is embedded in each article and its DOI record.
Copyright Holder
Copyright in all articles remains with the author(s). By submitting a manuscript, authors agree to grant the publisher (American Society for Inclusion, Diversity, and Equity in Healthcare – ASIDE) a non-exclusive license to publish and distribute the work under the terms of the CC BY 4.0 license.
Third-party Material
Any material (e.g., images, figures, or tables) not covered by CC BY 4.0 will be clearly indicated in the article. Users must obtain permission directly from the copyright holder for reuse of such third-party material.
Author Rights and Self-Archiving
Authors are permitted to deposit all versions of their work (preprint, author’s accepted manuscript, and version of record) in institutional or subject repositories of their choice immediately upon publication, without embargo, provided that the DOI and license information are included.
Downloads
Published
Issue
Section
Categories
How to Cite
Article history
- Received
- 23 Apr 2026
- Received in revised form
- 16 May 2026
- Accepted
- 6 Jun 2026
- Published
- 24 Jun 2026